Hepion reported a loss from operations of $4.8m in Q220, compared to $4.2m in Q120, along with R&D costs of $3.0m, compared to $2.6m in Q120. We believe strained pharmaceutical supply chains as a result of the pandemic have contributed to the increase in drug supply costs that pushed R&D expenses higher for a second consecutive quarter. As such, we have increased our FY20 R&D forecast from $9m to $10.3m.
21 Aug 2020
Hepion Pharmaceuticals - Increased operating expenses
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Hepion Pharmaceuticals - Increased operating expenses
Hepion Pharmaceuticals, Inc. (HEPA:NAS) | 0 0 0.0%
- Published:
21 Aug 2020 -
Author:
Dr Nathaniel Calloway -
Pages:
4
Hepion reported a loss from operations of $4.8m in Q220, compared to $4.2m in Q120, along with R&D costs of $3.0m, compared to $2.6m in Q120. We believe strained pharmaceutical supply chains as a result of the pandemic have contributed to the increase in drug supply costs that pushed R&D expenses higher for a second consecutive quarter. As such, we have increased our FY20 R&D forecast from $9m to $10.3m.